Private TB drug market might be fueling drug resistance, treatment failures
The surprisingly large and irregular practices of the private tuberculosis (TB) drug market could be driving treatment failures and the emergence of multi-drug resistance (MDR), according to a new report in the journal PLoS ONE. The study found the private TB drug market is now just as big as the public market, whereas previously TB […]